Chronic Lymphocytic Leukemia
Item
patients diagnosed with chronic lymphocytic leukemia
boolean
C0023434 (UMLS CUI [1])
fludarabine | Regimen fludarabine containing
Item
prior therapy with fludarabine or a fludarabine containing regimen
boolean
C0059985 (UMLS CUI [1])
C0040808 (UMLS CUI [2,1])
C0059985 (UMLS CUI [2,2])
C0332256 (UMLS CUI [2,3])
CD20 Expression Chronic Lymphocytic Leukemia Cells
Item
cd20 expression on cll cells
boolean
C0054946 (UMLS CUI [1,1])
C0017262 (UMLS CUI [1,2])
C0023434 (UMLS CUI [1,3])
C0007634 (UMLS CUI [1,4])
Absolute neutrophil count
Item
neutrophil count anc greater than 500/mm(3)
boolean
C0948762 (UMLS CUI [1])
Platelet Count measurement
Item
platelet count greater than 30k/mm(3)
boolean
C0032181 (UMLS CUI [1])
Age
Item
age 21-99
boolean
C0001779 (UMLS CUI [1])
Lymphadenopathy Bulky | Lymph nodes Quantity Diameter size
Item
bulky lymphadenopathy, defined as greater than 1 lymph node with greater than 5cm in largest diameter
boolean
C0497156 (UMLS CUI [1,1])
C1511341 (UMLS CUI [1,2])
C0024204 (UMLS CUI [2,1])
C1265611 (UMLS CUI [2,2])
C1301886 (UMLS CUI [2,3])
C0456389 (UMLS CUI [2,4])
Transformation High Grade Lymphoma Evidence of | Richter's syndrome
Item
evidence for transformation into high grade lymphoma (richter's transformation)
boolean
C3714584 (UMLS CUI [1,1])
C0079740 (UMLS CUI [1,2])
C0332120 (UMLS CUI [1,3])
C0349631 (UMLS CUI [2])
ECOG performance status
Item
ecog performance 3 or higher
boolean
C1520224 (UMLS CUI [1])
cancer treatment
Item
other concurrent anticancer therapies
boolean
C0920425 (UMLS CUI [1])
systemic therapy Chronic Lymphocytic Leukemia
Item
less than 3 months from last systemic therapy for cll
boolean
C1515119 (UMLS CUI [1,1])
C0023434 (UMLS CUI [1,2])
Monoclonal Antibody Therapy
Item
less than 6 months from last monoclonal antibody therapy
boolean
C0279694 (UMLS CUI [1])
rituximab Dose Quantity | rituximab Chemotherapy, multiple agents (combination regimen)
Item
more than 10 doses rituximab, within 12 months preceeding protocol enrollment, either as single agent or in a combination chemotherapy regimen
boolean
C0393022 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
C0393022 (UMLS CUI [2,1])
C3846439 (UMLS CUI [2,2])
Communicable Disease Clinical Significance | HIV Seropositivity | Hepatitis C
Item
chronic or current clinically significant infection, including hiv positivity or hepatitis c
boolean
C0009450 (UMLS CUI [1,1])
C2826293 (UMLS CUI [1,2])
C0019699 (UMLS CUI [2])
C0019196 (UMLS CUI [3])
Moribund | Liver disease Severe | Kidney Disease Severe | Heart Disease Severe | nervous system disorder Severe | Lung disease Severe | Communicable Disease Severe | Metabolic Disease Severe | Disease Severe Protocol Compliance Unable
Item
moribund status or concurrent hepatic, renal, cardiac, neurologic, pulmonary, infectious, or metabolic disease of such severity that it would preclude the patient's ability to tolerate protocol therapy
boolean
C0424547 (UMLS CUI [1])
C0023895 (UMLS CUI [2,1])
C0205082 (UMLS CUI [2,2])
C0022658 (UMLS CUI [3,1])
C0205082 (UMLS CUI [3,2])
C0018799 (UMLS CUI [4,1])
C0205082 (UMLS CUI [4,2])
C0027765 (UMLS CUI [5,1])
C0205082 (UMLS CUI [5,2])
C0024115 (UMLS CUI [6,1])
C0205082 (UMLS CUI [6,2])
C0009450 (UMLS CUI [7,1])
C0205082 (UMLS CUI [7,2])
C0025517 (UMLS CUI [8,1])
C0205082 (UMLS CUI [8,2])
C0012634 (UMLS CUI [9,1])
C0205082 (UMLS CUI [9,2])
C0525058 (UMLS CUI [9,3])
C1299582 (UMLS CUI [9,4])
Mucous Membrane Reaction | Paraneoplastic pemphigus | Stevens-Johnson Syndrome | Lichenoid Eruptions | Skin Diseases, Vesiculobullous | Toxic Epidermal Necrolysis
Item
history of mucocutaneous reactions (paraneoplastic pemphigus, stevens-johnson syndrome, lichenoid dermatitis, vesiculobullous dermatitis, and toxic epidermal necrolysis)
boolean
C0026724 (UMLS CUI [1,1])
C0443286 (UMLS CUI [1,2])
C1112570 (UMLS CUI [2])
C0038325 (UMLS CUI [3])
C0162848 (UMLS CUI [4])
C0037275 (UMLS CUI [5])
C0014518 (UMLS CUI [6])
Anaphylaxis Murine protein | IgE-mediated hypersensitivity Murine protein | Anaphylaxis Murine protein Component | IgE-mediated hypersensitivity Murine protein Component
Item
known anaphylaxis or ige mediated hypersensitivity to murine proteins or to any component of this product
boolean
C0002792 (UMLS CUI [1,1])
C1699668 (UMLS CUI [1,2])
C0020523 (UMLS CUI [2,1])
C1699668 (UMLS CUI [2,2])
C0002792 (UMLS CUI [3,1])
C1699668 (UMLS CUI [3,2])
C1705248 (UMLS CUI [3,3])
C0020523 (UMLS CUI [4,1])
C1699668 (UMLS CUI [4,2])
C1705248 (UMLS CUI [4,3])
Investigational New Drug Injection Self Unable
Item
inability to self inject the study medication or to have it administered by a third person
boolean
C0013230 (UMLS CUI [1,1])
C1533685 (UMLS CUI [1,2])
C0036588 (UMLS CUI [1,3])
C1299582 (UMLS CUI [1,4])
Study Protocol Comprehension Unable | Informed Consent
Item
inability to understand the investigational nature of the study ability to provide informed consent
boolean
C2348563 (UMLS CUI [1,1])
C0162340 (UMLS CUI [1,2])
C1299582 (UMLS CUI [1,3])
C0021430 (UMLS CUI [2])